Next Article in Journal
Long-Term Cross Immune Response in Mice following Heterologous Prime-Boost COVID-19 Vaccination with Full-Length Spike mRNA and Recombinant S1 Protein
Previous Article in Journal
Potency of Veterinary Rabies Vaccines Marketed in Sri Lanka
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 11
Issue 5
10.3390/vaccines11050962
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon

by
Mamun Al-Mahtab
1,*,†,
Sheikh Mohammad Fazle Akbar
2,*,†,
Osamu Yoshida
2,
Julio Cesar Aguilar
3,†,
Gerardo Guillen
3 and
Yoichi Hiasa
2
1
Interventional Hepatology Division, Department of Hepatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka 1000, Bangladesh
2
Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime 791-0295, Japan
3
Center for Genetic Engineering and Biotechnology, Havana 10400, Cuba
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2023, 11(5), 962; https://doi.org/10.3390/vaccines11050962
Submission received: 7 March 2023 / Revised: 29 April 2023 / Accepted: 30 April 2023 / Published: 9 May 2023
(This article belongs to the Section Hepatitis Virus Vaccines)
Browse Figures
Review Reports Versions Notes

Abstract

An open-level, randomized and treatment-controlled clinical trial has shown that a therapeutic vaccine containing hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) (NASVAC) is endowed with antiviral and liver protecting capacity and is safer than pegylated interferon (Peg-IFN) in patients with chronic hepatitis B (CHB). The present study provides information about the role of the hepatitis B virus (HBV) genotype in this phase III clinical trial. From a total of 160 patients enrolled in this trial, the HBV genotypes of 133 patients were characterized, and NASVAC induced a stronger antiviral effect (HBV DNA reduction below 250 copies per mL) than Peg-IFN. The antiviral effects and alanine aminotransferase levels were not significantly different among different HBV genotypes in NASVAC-treated patients. However, a significantly higher proportion of genotype-D patients receiving NASVAC showed better therapeutic effects, compared to genotype-D patients receiving Peg-IFN, with a marked difference of 44%. In conclusion, NASVAC seems to be a better alternative to Peg-IFN, especially in patients with HBV genotype-D patients. This reflects the attractiveness of NASVAC in countries where genotype D is highly prevalent. The mechanisms underlying the effect of HBV genotype are being studied in a new clinical trial.
Keywords: chronic hepatitis B; NASVAC; HBV genotype D; pegylated interferon; immune therapy chronic hepatitis B; NASVAC; HBV genotype D; pegylated interferon; immune therapy

Share and Cite

MDPI and ACS Style

Al-Mahtab, M.; Akbar, S.M.F.; Yoshida, O.; Aguilar, J.C.; Guillen, G.; Hiasa, Y. Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon. Vaccines 2023, 11, 962. https://doi.org/10.3390/vaccines11050962

AMA Style

Al-Mahtab M, Akbar SMF, Yoshida O, Aguilar JC, Guillen G, Hiasa Y. Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon. Vaccines. 2023; 11(5):962. https://doi.org/10.3390/vaccines11050962

Chicago/Turabian Style

Al-Mahtab, Mamun, Sheikh Mohammad Fazle Akbar, Osamu Yoshida, Julio Cesar Aguilar, Gerardo Guillen, and Yoichi Hiasa. 2023. "Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon" Vaccines 11, no. 5: 962. https://doi.org/10.3390/vaccines11050962

APA Style

Al-Mahtab, M., Akbar, S. M. F., Yoshida, O., Aguilar, J. C., Guillen, G., & Hiasa, Y. (2023). Antiviral Response across Genotypes after Treatment of Chronic Hepatitis B Patients with the Therapeutic Vaccine NASVAC or Pegylated Interferon. Vaccines, 11(5), 962. https://doi.org/10.3390/vaccines11050962

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop